醒脾养儿颗粒治疗小儿原发性夜间遗尿症的临床观察
x

请在关注微信后,向客服人员索取文件

篇名: 醒脾养儿颗粒治疗小儿原发性夜间遗尿症的临床观察
TITLE:
摘要: 目的:观察醒脾养儿颗粒治疗小儿原发性夜间遗尿症的疗效和安全性。方法:97例原发性夜间遗尿症患儿随机分为对照组(46例)和观察组(51例)。对照组患儿给予消旋山莨菪碱片0.5 mg/(kg·d),口服,每日1次+维生素B1片10 mg,口服,每日3次+谷维素片10 mg, 口服,每日3次+睡前30 min口服盐酸甲氯芬酯胶囊0.1 g,口服,每日1次。观察组患儿在对照组治疗的基础上加服醒脾养儿颗粒5~6岁0.4 g,7~14岁0.6 g , 每日3次。两组均连续治疗4周。观察两组患儿的临床疗效,治疗前后肾阳虚症状积分、唤醒阈、膀胱容量、膀胱容量壁厚指数(BVWI)、遗尿频率、血清精氨酸加压素(AVP)、环磷酸腺苷(cAMP)、环磷酸鸟苷(cGMP)、cAMP/cGMP,复发率及不良反应发生情况。结果:观察组患儿总有效率显著高于对照组,差异有统计学意义(P<0.01)。治疗后,两组患儿肾阳虚症状积分、唤醒阈、BVWI、遗尿频率、血清cGMP均显著低于同组治疗前, 且观察组显著低于对照组;两组患儿膀胱容量、血清AVP、cAMP、cAMP/cGMP均显著高于同组治疗前,且观察组显著高于对照组,差异均有统计学意义(P<0.01)。治疗3个月后,两组总有效患儿复发率比较,差异无统计学意义(P>0.05);治疗6个月后,观察组总有效患儿复发率显著低于对照组,差异有统计学意义(P<0.01)。两组患儿不良反应发生率比较,差异无统计学意义(P>0.05)。结论:在常规治疗的基础上,醒脾养儿颗粒治疗小儿原发性夜间遗尿症的疗效和安全性均较好,可改善患儿肾阳虚症状及唤醒阈,提高患儿的膀胱容量和血清AVP。
ABSTRACT: OBJECTIVE: To observe the efficacy and safety of Xingpi yang’er granule in the treatment of primary nocturnal enuresis in children. METHODS: 97 children with primary nocturnal enuresis were randomly divided into control group (46 cases) and observation group (51 cases). Control group received Racemic anisodamine tablet 0.5 mg/(kg.d), orally, once a day+Vitamin B1 tablet 10 mg, orally, 3 times a day+Oryzanol tablet 10 mg, orally, 3 times a day + Meclofenac hydrochloride capsule 0.1 g 30 min before going to bed, orally, once a day. Observation group was additionally received Xingpi yang’er granule 0.4 g for 5-6 years old and 0.6 g for 7-14 years old, 3 times a day. They were treated for 4 weeks. Clinical efficacy, kidney Yang deficiency score, wake-up threshold, bladder capacity, bladder volume,BVWI, enuresis frequency,AVP, cAMP,cGMP, cAMP/cGMP before and after treatment, recurrence rate and the incidence of adverse reactions in 2 groups were observed. RESULTS: The total effective rate in observation group was significantly higher than control group(P<0.01).  After treatment, the kidney Yang deficiency score, wake-up threshold, BVWI, enuresis frequency and cGMP in 2 groups were significantly lower than before, and observation group was significantly lower than control group; bladder capacity, serum AVP, cAMP and cAMP/cGMP in 2 groups were significantly higher than before, and observation group was significantly higher than control group(P<0.01). After 3 months, there was no significant difference in the recurrence rate in total effective children(P>0.05); after 6 months, the total effective rate recurrence rate in observation group was significantly lower than control group(P<0.01). And there was no significant difference in the incidence of adverse reactions (P>0.05). CONCLUSIONS: Based on conventional treatment, Xingpi yang’er granule shows good efficacy and safety in the treatment of primary nocturnal enuresis in children, which can improve children’s kidney Yang deficiency score, wake-up threshold and bladder capacity and serum AVP.
期刊: 2017年第28卷第6期
作者: 余益萍,田永波,刘颖,陈富菊
AUTHORS: YU Yiping,TIAN Yongbo,LIU Ying,CHEN Fuju
关键字: 醒脾养儿颗粒;小儿;原发性夜间遗尿症;疗效;安全性;血清精氨酸加压素
KEYWORDS: Xingpi yang’er granule; Children; Primary nocturnal enuresis; Efficacy; Safety; AVP
阅读数: 508 次
本月下载数: 4 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!